Prosecution Insights
Last updated: April 18, 2026
Application No. 17/748,634

THERMAL INTERFACE MATERIALS AND METHODS FOR APPLICATION

Final Rejection §103
Filed
May 19, 2022
Examiner
ZIMMER, MARC S
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Henkel AG & Co. KGaA
OA Round
4 (Final)
79%
Grant Probability
Favorable
5-6
OA Rounds
2y 7m
To Grant
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
1230 granted / 1549 resolved
+14.4% vs TC avg
Strong +16% interview lift
Without
With
+15.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
48 currently pending
Career history
1597
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
39.2%
-0.8% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1549 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Predicated on an indication of allowable subject matter in claim 18, Applicant has simply cancelled the claims subject to rejection leaving as pending claims 18-23. However, upon further scrutiny of the Iwata (WO ‘501) disclosure it was discovered that the subject matter of Example 1 had been misread and the subject matter of claim 18 should, likewise, have been deemed unpatentable. The Examiner sincerely regrets that Applicant had not been correctly apprised of the status of these claims at an earlier stage of prosecution. Claim Rejections - 35 USC § 103 Claims 18-23 are rejected under 35 U.S.C. 103 as being unpatentable over Iwata et al., WO 2021/095501 in view of Hu et al., WO 2020/093258 and/or U.S. 2018/0030327 and/or the YouTube video entitled "Application of Thermal Interface Material" available at the URL https://www.youtube.com/watch?v=AtTaAUd6-js. Iwata (WO ‘501), Hu, and Zhang are all germane for the reasons outlined previously with the caveat that the Examiner had previously concluded that a hydrosilyl group-terminated polydimethylsiloxane chain extender had not been disclosed but his earlier construal was incorrect. Example 1-1 of Iwata does not teach the incorporation of 10.6 total parts of a methylhydrogensiloxane crosslinking compound adhering to formula (6) as had been earlier asserted. Instead, 1.26 g of said crosslinker is added and subsequently 9.4 parts of a chain extender (8) anticipatory of the siloxane contained within the second reactant composition is introduced. The calculated amount of the chain extender as a fraction of the total is 0.83% which, while lower than 1%, is not substantially lower and, to reiterate, there is nothing in the current record that suggests 1 wt.% to represent a critical endpoint below which the invention is inoperable. A prima facie case of obviousness exists where the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected [the claimed product and a product disclosed in the prior art] to have the same properties.” Titanium Metals Corp. of America v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985) As before, Iwata is silent as to the provision of the curable composition to a vessel, and more precisely a syringe, from which it can later be dispensed but Hu, Zhang, and the YouTube video verify this aspect to be obvious and widely practiced. Although there is no express suggestion of keeping the curable composition in said vessel for at least 24 hours prior to use, it is understood that the composition-filled vessel represents a form for commercial sale and that the mixture would reside in the syringe for much more than 24 hours. Paragraph [0190] says that curing conditions are the same as are conventionally known, and 40° to 180° C for 1 minute to hour in particular. Subject matter addressing the limitations of claims 20-23 is summarized in the text of the previous Office action dated November 26, 2025. Finality of the rejection is withdrawn given that Applicant had not previously been confronted with the rejections formulated herein. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARC S ZIMMER whose telephone number is (571)272-1096. The examiner can normally be reached M-F 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. January 12, 2026 /MARC S ZIMMER/Primary Patent Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

May 19, 2022
Application Filed
Jan 08, 2025
Non-Final Rejection — §103
Apr 04, 2025
Response Filed
Nov 24, 2025
Final Rejection — §103
Jan 06, 2026
Response after Non-Final Action
Jan 12, 2026
Non-Final Rejection — §103
Mar 09, 2026
Response Filed
Mar 26, 2026
Applicant Interview (Telephonic)
Mar 26, 2026
Examiner Interview Summary
Apr 09, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600882
SILICONE COMPOSITIONS CONTAINING ACRYLATE CURE ACCELERATOR
2y 5m to grant Granted Apr 14, 2026
Patent 12590186
FLUOROSILICONE POLYMERS, COMPOSITIONS, AND USES THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12583209
MULTILAYER BODY COMPOSED OF CURED ORGANOPOLYSILOXANE FILMS, USE OF SAME, AND METHOD FOR PRODUCING SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12584008
POLYOLEFIN COMPOSITION FOR ROOFING APPLICATIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12584053
SILANE FUNCTIONALIZED ROSINS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.6%)
2y 7m
Median Time to Grant
High
PTA Risk
Based on 1549 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month